GLP-1 Weight Loss Drugs Are Eating Away at Muscle and Gut Health

GLP-1 receptor agonists like semaglutide and tirzepatide have become the default prescription for obesity, but a new systematic review argues the drugs solve one problem while quietly creating another: malnutrition. After compiling clinical trial and cohort data published between January 2024 and May 2026, researchers found that a fifth to a third of the weight patients lose on these drugs is muscle, not fat, and that fewer than one in ten patients manage to eat enough protein to prevent it. The review, published in the International Journal of Nutrition, argues the fix isn't willpower, it's food technology, including a proposed role for postbiotics in repairing the gut microbiome the drugs disrupt.

GLP-1 Drugs Drain 20 to 30 Percent Muscle, Not Fat

The core finding, laid out in a systematic review published in the International Journal of Nutrition, is blunt: "muscle wasting comprises 20% to 30% of the overall weight reduction achieved with incretin therapies." As a rough illustration of that ratio, a patient who loses 40 pounds on one of these drugs may be shedding 8 to 12 pounds of lean tissue along with the fat. The mechanism traces back to how GLP-1 receptor agonists work in the first place: they slow gastric emptying and suppress appetite so effectively that patients eat far less of everything, protein included, not just the calories they're trying to cut. A 2024 analysis of lean body mass changes on GLP-1 therapies in Diabetes, Obesity and Metabolism reached similar figures, and drugmakers have since begun testing muscle-preserving add-on therapies to blunt the effect.

Fewer Than 1 in 10 Patients Hit Protein Targets

The review's most striking practical number isn't about the drugs' efficacy but about what patients are actually eating: less than 10% of patients meet baseline protein guidelines, and in some cases daily energy intake falls under 800 kcal a day, roughly a third of what most adults need. That kind of restriction is what nutritionists describe as a semi-starvation intake pattern, and it disproportionately threatens older adults and anyone with limited muscle reserve to begin with, since lean mass is what preserves strength, metabolic rate, and glucose control long after the weight comes off. Harvard Health has separately reported on rising nutrient deficiency risk among GLP-1 users, and Mayo Clinic's patient guidance now specifically addresses muscle loss and supplementation for people on these drugs, a sign the concern has moved from the research literature into routine clinical counseling.

A Two-Year Sweep of PubMed and ScienceDirect Literature

Rather than running a new trial, the authors built their case by systematically searching PubMed, ScienceDirect, and Google Scholar for studies published between January 2024 and May 2026 on GLP-1 receptor agonists' nutritional side effects, then synthesizing the results with food-biotechnology research aimed at mitigating them. That approach lets the review pull together numbers from many separate trials and cohorts that individually might not have made headlines on their own, but it also means the paper is a synthesis of other people's data rather than a fresh measurement of its own, and it doesn't spell out how much the underlying studies varied in design or population.

The Postbiotic Fix Is Proposed, Not Yet Proven

The review's least settled claim is also its most interesting one: that specific postbiotics, the inactive or fragment byproducts of beneficial bacteria, could help stabilize a gut microbiome disrupted by GLP-1 therapy's slowed digestion and reduced food intake. That idea has real biological grounding. Research on the crosstalk between GLP-1 signaling and gut microbiota shows the two systems are deeply intertwined, with bacterial metabolites like butyrate influencing the same hormone pathway the drugs target. But grounding isn't proof: the review doesn't point to a dedicated randomized trial testing postbiotics in GLP-1 patients specifically, and the excerpt available doesn't disclose whether its authors have financial ties to food-biotech companies that would stand to benefit from the mitigations they recommend.

Protein Hydrolysates and Microencapsulated Nutrients Are Next

The review lays out three specific fixes it wants industry and clinicians to pursue. High-biological-value protein hydrolysates, pre-broken-down proteins that are easier to absorb in small quantities, are proposed to trigger muscle protein synthesis through the mTOR pathway even when patients can only manage small meals. Microencapsulated vitamins and minerals are meant to preserve nutrient bioaccessibility despite the drugs' delayed gastric emptying. And postbiotics would round out the strategy by supporting the gut environment itself. None of these are approved add-ons to GLP-1 prescriptions today, they're a research agenda, not a treatment plan, but the surge of patients now taking these drugs long-term is likely to push dedicated trials of muscle-and-microbiome-protective nutrition products into clinical testing sooner rather than later.

References

1. Oluwaseun Anyiam, Arash Ardavani, Rushdina Sofia Abdul Rashid, Avinash Panesar, Iskandar Idris (2025). How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis. Obesity Reviews. https://doi.org/10.1111/obr.13916
2. Ian J. Neeland, Jennifer Linge, Andreas L. Birkenfeld (2024). Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15728
3. GLP-1 drugs and nutrient deficiency risk (Harvard Health). health.harvard.edu. https://www.health.harvard.edu/diet-and-nutrition/study-taking-glp-1-drugs-may-increase-risk-of-key-nutrient-deficiencies
4. GLP-1 signaling and gut microbiota crosstalk (PMC). NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC10790698/